重组人血管内皮抑素治疗初治广泛期小细胞肺癌的效果

Efficacy of Recombinant Human Endostatin in the Treatment of Newly Diagnosed Extensive Small Cell Lung Cancer

目的:评价初治的广泛期小细胞肺癌(SCLC)患者接受依托泊苷和顺铂化疗(EP方案)联合重组人血管内皮抑制素注射液治疗对比单独EP方案化疗是否具有更好的临床效果。方法:选取本院2017年3月-2019年9月收治的60例广泛期小细胞肺癌初治患者作为研究对象,采取随机分配方式,按1∶1分为试验组(重组人血管内皮抑素联合EP方案)和对照组(EP方案),对比两组的有效性与安全性。结果:试验组的疾病控制率为96.7%,高于对照组的73.3%(P<0.05)。试验组PFS略长于对照组,两组比较差异无统计学意义(P>0.05),试验组Ⅲ级不良反应发生率为0,低于对照组的26.7%(P<0.05)。结论:广泛期小细胞肺癌初治患者的临床治疗中,应用依托泊苷和顺铂进行化疗的基础上,联合应用重组人血管内皮抑素,能够有效提高疾病控制率,降低化疗毒副反应的发生,以提高患者生活质量。

Objective:To evaluate the efficacy of Etoposide and Cisplatin chemotherapy combined with Recombinant Human Vascular Endostatin Injection in the treatment of patients with extensive small cell lung cancer(SCLC)compared with EP project alone.Method:A total of 60 patients with extensive small cell lung cancer who treated in our hospital from March 2017 to September 2019 were randomly divided into the experimental group(Recombinant Human Endostatin Injection combined with EP project)and the control group(EP project),with 30 cases in each group.The effectiveness and safety in two groups were compared.Result:DCR of the experimental group was 96.7%,which was higher than 73.3%of the control group(P<0.05).PFS of the experimental group was longer than that of the control group,but there was no statistically significant difference in PFS between the two groups(P>0.05).The incidence rate ofⅢgrade adverse reactions in the experimental group was 0,which was lower than 26.7%of the control group(P<0.05).Conclusion:The combination of Etoposide and Cisplatin with Recombinant Human Vascular Endostatin can improve the rate of disease control,reduce the occurrence of side effects of chemotherapy and improve the life quality of patients with extensive small cell lung cancer.